Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.
Oncology, Medical October 17th 2023
Don’t miss this crucial update on how biomarker-guided first-line treatment can substantially improve survival rates in advanced NSCLC patients.
Oncology, Medical October 9th 2023
Medical Professionals Reference (MPR)
Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.
Oncology Learning Network
New research indicates that PCI offers significant survival advantages over TRT in treating extensive-stage small cell lung cancer, challenging existing treatment protocols.
Oncology, Medical October 2nd 2023
Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.
Oncology, Medical September 25th 2023
Dana-Farber Cancer Institute
Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH